Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Novartis Pharmaceuticals UK Ltd
Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Telephone: +44 (0)1276 692 255
Fax: +44 (0)1276 698 449
Medical Information Direct Line: +44 (0)1276 698 370
Medical Information e-mail: medinfo.uk@novartis.com
Customer Care direct line: +44 (0)845 741 9442

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 04/04/2012
PIL Xolair 150 mg powder and solvent for solution for injection

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 04/04/2012 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to name of manufacturer
Updated on 08/07/2011 and displayed until 04/04/2012
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to MA holder contact details
Updated on 27/09/2010 and displayed until 08/07/2011
Reasons for adding or updating:
  • Change/addition of instructions for reconstitution and/ or administration
  • Change to Further Information section
  • Change to side-effects
Updated on 19/02/2010 and displayed until 27/09/2010
Reasons for adding or updating:
  • Change to dosage and administration
  • Change to MA holder contact details
Updated on 03/09/2009 and displayed until 19/02/2010
Reasons for adding or updating:
  • Change to, or new, use for medicine
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Change to dosage and administration
Updated on 12/02/2009 and displayed until 03/09/2009
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change of contra-indications
  • Change to instructions about missed dose
  • Change to storage instructions
  • Change to side-effects
  • Change to drug interactions
  • Change to information about pregnancy or lactation
Updated on 10/04/2008 and displayed until 12/02/2009
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 01/08/2007 and displayed until 10/04/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 17/03/2006 and displayed until 01/08/2007
Reasons for adding or updating:
  • Change to date of revision
Updated on 02/11/2005 and displayed until 17/03/2006
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 31/10/2005 and displayed until 02/11/2005
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
  omalizumab